Fig. 1: Actin staining of engineered [hair-] cells at day 33, cultivated in a bioprinted skin scaffolds for upscaled HAIROID cultivation.
Our R&D resumed in Q3/2020, with the start of further experiments in new laboratories and the hiring of additional PI’. Structured de-risking of the HAIROID project will conclude, with CLINICAL PHASE 1 (toxicology/dynamics) earliest in Q4/ 2023. We expect a finalized EMA approval earliest in Q4 2026.